<DOC>
	<DOCNO>NCT01730209</DOCNO>
	<brief_summary>Tuberous sclerosis complex ( TSC ) genetic disease lead mental retardation 50 % patient , learn problem , behavioral problem , autism epilepsy 90 % patient . The underlie deficit TSC , loss inhibition mammalian target rapamycin ( mTOR ) protein due dysfunction tuberin/hamartin protein complex , rescue everolimus . Everolimus register treatment renal cell carcinoma giant cell astrocytoma ( SEGA ) . Evidence human animal study suggest mTOR inhibitor improve learn development patient TSC .</brief_summary>
	<brief_title>Efficacy RAD001/Everolimus Autism NeuroPsychological Deficits Children With Tuberous Sclerosis Complex</brief_title>
	<detailed_description>Randomized double-blind placebo control intervention study child TSC age 4 15 year intelligence quotient ( IQ ) estimate &lt; 80 and/or special school and/or autism spectrum disorder and/or learn disability require remedial teaching . Patients randomise receive everolimus placebo period 12 month .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Tuberous Sclerosis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Children definite diagnosis TSC 4 15 year . With IQ estimate &lt; 80 and/or special school and/or autism spectrum disorder and/or learn disability require remedial teaching . Written inform consent parents/caretakers , patient 12 year older cognitively able consent . In girls menarche , appropriate contraception must use abstinence practice . Hepatic dysfunction Surgery &lt; 6wk Current infection time inclusion Developmental age estimate 3.5 year Intractable epilepsy 1 seizure/week Inability comply treatment protocol Additional diseases disorder may influence endpoint , include : SEGA require treatment Uncontrolled diabetes mellitus Known impaired lung function Allergy component study medication Prior treatment mTOR inhibitor HIV seropositivity Bleeding diathesis oral antivitamin K medication Serum creatinine &gt; 1.5 x ULN Uncontrolled hyperlipidemia ( fast serum cholesterol &gt; 7.75 mmol/L , fast serum triglyceride &gt; 2.5 x ULN ) Use investigational drug within 30 day prior inclusion History myocardial infarction , angina stroke related atherosclerosis , organ transplantation , malignancy past 2 year Pregnancy breastfeed Children risk Hepatitis B ( HB ) , unless hepatitis B serology normal . Risk group child live Asia , Africa , Central South America , Eastern Europe , Spain , Portugal , Greece , child know suspect past current hepatitis B infection , current prior IV illicit drug use , current prior dialysis , household contact hepatitis B infect patient ( ) , current prior highrisk sexual activity , body pierce tattoo , mother know hepatitis B history . If vaccinate , presence HBs Ab normal . Known suspected hepatitis C infection , unless hepatitis C serology normal .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Tuberous Sclerosis Complex</keyword>
	<keyword>TSC</keyword>
	<keyword>Autism</keyword>
	<keyword>Learning problem</keyword>
	<keyword>Everolimus</keyword>
	<keyword>RAD001</keyword>
	<keyword>Treatment</keyword>
	<keyword>Cognition</keyword>
	<keyword>Intellectual disability</keyword>
</DOC>